References
- 1. Jaffe ES, Harris NL, Stein H, Vardiman JW, Eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, vol 3. Lyon, France: IARC Press, 2001.
- 2. Heim S, Mitelman F, Eds. Chronic myeloproliferative didorders. In: Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells, 2nd ed. New York, NY: Wiley-Liss. 1995: 166-172.
- 3. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases. Br J Haematol. 1997; 98(1): 96-102.
- 4. Dupriez B, Morel P, Demory JL, Simon M, Plantier I, Bauters F. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood. 1996; 88(3): 1013-1018.
- 5. Baxter EJ, Scott LM, Campbell P, East C, Forouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464): 1054-1061.
- 6. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17): 1779-1790.
- 7. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7(4): 387-397.
- 8. Steensma DP, Dewald GW, Lasho TL. The JAK2 V617F activating tyrosine kinase mutation is an infrequent eventh in both “atypical” myeloproliferative disorders and myelodisplastic syndromes. Blood. 2005; 106(4): 1207-1209.
- 9. Huret JL. t(3;12)(q26;q21). Atlas Genet Cytogenet Oncol Haematol. 2007. (http://AtlasGeneticsOncology. org/Anomalies/t0312q26q-21ID1280. html).
- 10. Shaffer LG, Tommerup N, Eds. An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger, 2005.
- 11. Andrieux J, Demory JL, Morel P, Plantier I, Dupriez B, Caulier MT, et al. Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia.Cancer Genet Cytogenet. 2002; 137(1): 68-71.
- 12. Nunoda K, Sashida G, Ohyashiki K, Kodama A, Fukutake K. The translocation (4;12)(q31;q21) in myelofibrosis associated with myelodysplastic syndrome: Impact of the 12q21 breakpoint. Cancer Genet Cytogenet. 2006; 164(1): 90-91.
- 13. Przepiorka D, Bryant E, Kidd P. Idiopathic myelofibrosis in blast transformation with 4;12 and 5;12 translocation and a 7q deletion. Cancer Genet Cytogenet. 1988; 30(1): 139-144.
- 14. Cho HS, Hyun MS. A novel jumping translocation of 12q21 in a patient with chronic idiopathic myelofibrosis. Korean J Hematol. 2006; 41(2): 99-104.
- 15. Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N, et al. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer. 2006; 45(4): 349-356.
- 16. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 1997; 80(4): 708-719.
- 17. Jones AV, Kreil S, Zoi K. Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106(6): 2162-2168.
- 18. Ahmed A, Chang CC. Chronic idiopathic myelofibrosis. Arch Pathol Lab Med .2006; 130(8): 1133-1143.